Group 1 - The core point of the news is that 基石药业 has entered into an exclusive strategic partnership with Istituto Gentili for the commercialization of Shugli monoclonal antibody in Western Europe and the UK, covering 23 countries [1][2] - According to the agreement, Gentili will receive exclusive commercialization rights for Shugli in 23 countries, including 18 EEA countries and the UK, Andorra, Monaco, San Marino, and Vatican City [1] - The total transaction amount can reach up to $192.5 million, which includes upfront payments and milestone payments related to registration and sales [1] Group 2 - Shugli is the first PD-L1 monoclonal antibody approved for first-line treatment of stage IV non-small cell lung cancer (NSCLC) in the EU and the UK, with a new indication application for stage III NSCLC already accepted by the European Medicines Agency (EMA) [2] - The partnership with Gentili is seen as an ideal collaboration to accelerate the accessibility of Shugli in the European market, especially in light of the ongoing changes in the US drug pricing system [2] - The company has already established four regional collaborations for Shugli in Europe, the Middle East, Africa, and Latin America, covering over 60 countries and regions, with plans to expand into Southeast Asia and Canada [2]
基石药业-B与Istituto Gentili就舒格利单抗在西欧和英国达成独家战略合作